Literature DB >> 9554885

Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.

J Poncet1, M Busquet, F Roux, A Pierré, G Atassi, P Jouin.   

Abstract

The natural cytotoxic compounds dolastatins 10 and 15 exhibit great similarities in structure and in their biological activity profiles. Two compounds (1 and 2) formed by interchanging the dolaisoleuine residue of dolastatin 10 and the MeVal-Pro dipeptide of dolastatin 15 were synthesized in order to evaluate the possible equivalence of these units. These compounds can be considered as chimeras of dolastatins 10 and 15 formed by the N-terminal part of the former and the C-terminal part of the latter and vice versa. Both analogues exhibited a marked decrease in their cytotoxic activity but showed similar differential cytotoxicity with regard to the cell lines assayed compared with the parent compounds. HT-29 cell line was the least sensitive one. However, this activity was in the nanomolar level and close to that of vincristine. The differences in their effect on tubulin polymerization were less pronounced. We confirmed the already known crucial role of the Dil residue in this assay. The nonequivalence of the Dil unit and the MeVal-Pro dipeptide probably reflects modification in the relative positions of the N-dimethylamino and the phenyl moieties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554885     DOI: 10.1021/jm970800t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Evolution of the total syntheses of ustiloxin natural products and their analogues.

Authors:  Pixu Li; Cory D Evans; Yongzhong Wu; Bin Cao; Ernest Hamel; Madeleine M Joullié
Journal:  J Am Chem Soc       Date:  2008-01-30       Impact factor: 15.419

Review 2.  Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.

Authors:  Gang Gao; Yanbing Wang; Huiming Hua; Dahong Li; Chunlan Tang
Journal:  Mar Drugs       Date:  2021-06-24       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.